SCHEMBL6018342

SCHEMBL6018342

CN(CCC1CCC(CN2CCCC2)CC1)S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.48
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CXCR4 P61073 2/20 0.44
MMP1 P03956 1/20 0.43
MMP2 P08253 1/20 0.43
MMP3 P08254 1/20 0.43
MMP8 P22894 1/20 0.43
MMP13 P45452 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
TSHR P16473 1/20 0.42
KDM2B Q8NHM5 2/20 0.41
PSEN1 P49768 2/20 0.41
PSEN2 P49810 2/20 0.41
APH1B Q8WW43 2/20 0.41
NCSTN Q92542 2/20 0.41
APH1A Q96BI3 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6018345 1.00 SIGMAR1 (0.48) SIGMAR1HTR2AHTR2CL3MBTL1CXCR4
SCHEMBL6019910 0.99 SIGMAR1 (0.50) SIGMAR1HTR2AHTR2CL3MBTL1CXCR4
SCHEMBL6019918 0.99 SIGMAR1 (0.50) SIGMAR1HTR2AHTR2CL3MBTL1CXCR4
SCHEMBL6019344 0.89 SIGMAR1 (0.56) SIGMAR1HTR2AHTR2CL3MBTL1CXCR4
SCHEMBL6019348 0.89 SIGMAR1 (0.56) SIGMAR1HTR2AHTR2CL3MBTL1CXCR4
SCHEMBL6019881 0.85 HTR2A (0.48) SIGMAR1HTR2AHTR2CCXCR4KDM2B
SCHEMBL6019877 0.85 HTR2A (0.48) SIGMAR1HTR2AHTR2CCXCR4KDM2B
SCHEMBL6019105 0.83 TSHR (0.46) HTR2AHTR2CL3MBTL1TSHRPSEN1
SCHEMBL6019100 0.83 TSHR (0.46) HTR2AHTR2CL3MBTL1TSHRPSEN1
SCHEMBL6019206 0.81 HTR2C (0.43) HTR2AHTR2CL3MBTL1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456171-B1 SUBSTITUTED CYCLOHEXANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2006-12-20 EP disclosed
US-20050272774-A1 Substituted cyclohexane derivatives ACKERMANN JEAN 2005-12-08 US disclosed
US-6953806-B2 Substituted cyclohexane derivatives HOFFMANN-LA ROCHE INC. (US) 2005-10-11 US disclosed
EP-1456171-A1 SUBSTITUTED CYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-09-15 EP disclosed
US-20030199550-A1 Substituted cyclohexane derivatives F.HOFFMANN-LA ROCHE AG (CH) 2003-10-23 US disclosed
WO-2003053919-A1 SUBSTITUTED CYCLOHEXANE DERIVATIVES F. HOFFMANN-LA-ROCHE AG (CH) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272774-A1 Substituted cyclohexane derivatives LSS, CYP51A1, CYP8B1 SIGMAR1 3008/4885HTR2A 3071/4885HTR2C 3745/4885
US-20030199550-A1 Substituted cyclohexane derivatives CYP51A1, LSS, CYP46A1 SIGMAR1 2490/4885HTR2A 3269/4885HTR2C 3643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.